In this study, we observed an upregulation of the myeloid antigens CD13/CD33 on CMPs and MEPs of patients with both low-risk MDS and MDS-EB, confirming this marker combination to be useful in the diagnosis of low-risk MDS [18,29]. Here, CD33 is linked to myelodysplastic syndrome.